Long non-coding RNA-non-coding RNA activated by DNA damage inhibition suppresses hepatic stellate cell activation via microRNA-495-3p/sphingosine 1-phosphate receptor 3 axis

Hepatic fibrosis is a damage repair response caused by multiple factors. A growing body of research suggests that long non-coding RNAs (lncRNAs) are involved in a wide range of biological processes, and thus regulate disease progression, including hepatic fibrosis. In this study, we investigated the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioengineered 2022-03, Vol.13 (3), p.6150-6162
Hauptverfasser: Zou, Lei, Shi, Cuifen, Wang, Dawei, Cheng, Juan, Wang, Qi, Wang, Lei, Yang, Guoya
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 6162
container_issue 3
container_start_page 6150
container_title Bioengineered
container_volume 13
creator Zou, Lei
Shi, Cuifen
Wang, Dawei
Cheng, Juan
Wang, Qi
Wang, Lei
Yang, Guoya
description Hepatic fibrosis is a damage repair response caused by multiple factors. A growing body of research suggests that long non-coding RNAs (lncRNAs) are involved in a wide range of biological processes, and thus regulate disease progression, including hepatic fibrosis. In this study, we investigated the mechanisms of the long non-coding RNA-non-coding RNA activated by DNA damage (NORAD) in modulating hepatic fibrosis development. Platelet-derived growth factor-BB (PDGF-BB) was used to activate LX-2 hepatic stellate cells (HSCs). The expression of NORAD and microRNA (miR)-495-3p was determined by quantitative real-time polymerase chain reaction (qRT-PCR) analysis. The effects of PDGF-BB on LX-2 cell viability, migration, invasion, and apoptosis were evaluated using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), Transwell, flow cytometry, and Western blot assays. The activation of HSCs was further verified by examining the expression of the typical markers, alpha smooth muscle actin (α-SMA) and collagen I (Col1α1), using qRT-PCR and Western blot assays. StarBase and dual-luciferase reporter assays were used to assess the binding relationship between miR-495-3p and NORAD. The NORAD levels remarkably increased, whereas the miR-495-3p levels decreased, in PDGF-BB-treated LX-2 cells. miR-495-3p was a putative downstream target of NORAD. NORAD silencing played an anti-fibrotic role by targeting miR-495-3p; this was accomplished by hindering PDGF-BB-treated LX-2 cell viability, migration, and invasion, decreasing the levels of α-SMA and Col1α1, and promoting apoptosis. miR-495-3p protected against hepatic fibrosis by inhibiting sphingosine 1-phosphate receptor 3 (S1PR3) expression. In summary, NORAD silencing inhibited hepatic fibrosis by suppressing HSC activation via the miR-495-3p/S1PR3 axis.
doi_str_mv 10.1080/21655979.2022.2037841
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2632798300</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2632798300</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-a86e347c713d4b68b4fa65c4f3b69639853f7967a5be9d677a10b21a05064a893</originalsourceid><addsrcrecordid>eNp9UcmO1DAQjRCIGQ3zCSAfuWTGjuPtghgNq9QCCcHZqjhOt1FiB9vd0B_FP-LQi5gLF5er_BarXlU9J_iGYIlvG8IZU0LdNLhpykGFbMmj6nKZ10xJ8fh8F-qiuk7pO8aYYNoyIZ9WF5Q1f9vL6vcq-DXywdcm9K5cv3y6qx-2CEx2O8i2R90evSmDHiZYW-T8xnUuu-BR2s5ztCnZhDZ2huwMStmOY2EhU-pJY8HuHKDJmRgWq1axms63ad4Ut5Cct4jU8yaUwcKN1tg5h4gogl8uPaueDDAme32sV9W3d2-_3n-oV5_ff7y_W9Wm5TLXILmlrTCC0L7tuOzaATgz7UA7rjhVktFBKC6AdVb1XAgguGsIYIZ5C1LRq-rVQXfedpPtjfU5wqjn6CaIex3A6Ycv3m30Ouy0VKLIkyLw8igQw4-tTVlPLi2LAG_DNumG00YoSTEuUHaAlo2kFO1wtiFYL2nrU9p6SVsf0y68F__-8cw6ZVsArw8A54cQJ_gZ4tjrDPsxxCGCNy5p-n-PP7rSu0Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2632798300</pqid></control><display><type>article</type><title>Long non-coding RNA-non-coding RNA activated by DNA damage inhibition suppresses hepatic stellate cell activation via microRNA-495-3p/sphingosine 1-phosphate receptor 3 axis</title><source>MEDLINE</source><source>Taylor &amp; Francis Open Access(OpenAccess)</source><source>PubMed (Medline)</source><source>EZB Electronic Journals Library</source><creator>Zou, Lei ; Shi, Cuifen ; Wang, Dawei ; Cheng, Juan ; Wang, Qi ; Wang, Lei ; Yang, Guoya</creator><creatorcontrib>Zou, Lei ; Shi, Cuifen ; Wang, Dawei ; Cheng, Juan ; Wang, Qi ; Wang, Lei ; Yang, Guoya</creatorcontrib><description>Hepatic fibrosis is a damage repair response caused by multiple factors. A growing body of research suggests that long non-coding RNAs (lncRNAs) are involved in a wide range of biological processes, and thus regulate disease progression, including hepatic fibrosis. In this study, we investigated the mechanisms of the long non-coding RNA-non-coding RNA activated by DNA damage (NORAD) in modulating hepatic fibrosis development. Platelet-derived growth factor-BB (PDGF-BB) was used to activate LX-2 hepatic stellate cells (HSCs). The expression of NORAD and microRNA (miR)-495-3p was determined by quantitative real-time polymerase chain reaction (qRT-PCR) analysis. The effects of PDGF-BB on LX-2 cell viability, migration, invasion, and apoptosis were evaluated using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), Transwell, flow cytometry, and Western blot assays. The activation of HSCs was further verified by examining the expression of the typical markers, alpha smooth muscle actin (α-SMA) and collagen I (Col1α1), using qRT-PCR and Western blot assays. StarBase and dual-luciferase reporter assays were used to assess the binding relationship between miR-495-3p and NORAD. The NORAD levels remarkably increased, whereas the miR-495-3p levels decreased, in PDGF-BB-treated LX-2 cells. miR-495-3p was a putative downstream target of NORAD. NORAD silencing played an anti-fibrotic role by targeting miR-495-3p; this was accomplished by hindering PDGF-BB-treated LX-2 cell viability, migration, and invasion, decreasing the levels of α-SMA and Col1α1, and promoting apoptosis. miR-495-3p protected against hepatic fibrosis by inhibiting sphingosine 1-phosphate receptor 3 (S1PR3) expression. In summary, NORAD silencing inhibited hepatic fibrosis by suppressing HSC activation via the miR-495-3p/S1PR3 axis.</description><identifier>ISSN: 2165-5979</identifier><identifier>EISSN: 2165-5987</identifier><identifier>DOI: 10.1080/21655979.2022.2037841</identifier><identifier>PMID: 35200103</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Becaplermin - pharmacology ; Biological Phenomena ; Cell Proliferation ; DNA Damage ; hepatic fibrosis ; hepatic stellate cells ; Hepatic Stellate Cells - metabolism ; Hepatic Stellate Cells - pathology ; Humans ; Liver Cirrhosis - genetics ; Liver Cirrhosis - pathology ; lncRNA NORAD ; MicroRNAs - metabolism ; miR-495-3p ; Research Paper ; RNA, Long Noncoding - metabolism ; S1PR3 ; Sphingosine-1-Phosphate Receptors</subject><ispartof>Bioengineered, 2022-03, Vol.13 (3), p.6150-6162</ispartof><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2022</rights><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2022 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-a86e347c713d4b68b4fa65c4f3b69639853f7967a5be9d677a10b21a05064a893</citedby><cites>FETCH-LOGICAL-c468t-a86e347c713d4b68b4fa65c4f3b69639853f7967a5be9d677a10b21a05064a893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973981/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973981/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27483,27905,27906,53772,53774,59122,59123</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35200103$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zou, Lei</creatorcontrib><creatorcontrib>Shi, Cuifen</creatorcontrib><creatorcontrib>Wang, Dawei</creatorcontrib><creatorcontrib>Cheng, Juan</creatorcontrib><creatorcontrib>Wang, Qi</creatorcontrib><creatorcontrib>Wang, Lei</creatorcontrib><creatorcontrib>Yang, Guoya</creatorcontrib><title>Long non-coding RNA-non-coding RNA activated by DNA damage inhibition suppresses hepatic stellate cell activation via microRNA-495-3p/sphingosine 1-phosphate receptor 3 axis</title><title>Bioengineered</title><addtitle>Bioengineered</addtitle><description>Hepatic fibrosis is a damage repair response caused by multiple factors. A growing body of research suggests that long non-coding RNAs (lncRNAs) are involved in a wide range of biological processes, and thus regulate disease progression, including hepatic fibrosis. In this study, we investigated the mechanisms of the long non-coding RNA-non-coding RNA activated by DNA damage (NORAD) in modulating hepatic fibrosis development. Platelet-derived growth factor-BB (PDGF-BB) was used to activate LX-2 hepatic stellate cells (HSCs). The expression of NORAD and microRNA (miR)-495-3p was determined by quantitative real-time polymerase chain reaction (qRT-PCR) analysis. The effects of PDGF-BB on LX-2 cell viability, migration, invasion, and apoptosis were evaluated using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), Transwell, flow cytometry, and Western blot assays. The activation of HSCs was further verified by examining the expression of the typical markers, alpha smooth muscle actin (α-SMA) and collagen I (Col1α1), using qRT-PCR and Western blot assays. StarBase and dual-luciferase reporter assays were used to assess the binding relationship between miR-495-3p and NORAD. The NORAD levels remarkably increased, whereas the miR-495-3p levels decreased, in PDGF-BB-treated LX-2 cells. miR-495-3p was a putative downstream target of NORAD. NORAD silencing played an anti-fibrotic role by targeting miR-495-3p; this was accomplished by hindering PDGF-BB-treated LX-2 cell viability, migration, and invasion, decreasing the levels of α-SMA and Col1α1, and promoting apoptosis. miR-495-3p protected against hepatic fibrosis by inhibiting sphingosine 1-phosphate receptor 3 (S1PR3) expression. In summary, NORAD silencing inhibited hepatic fibrosis by suppressing HSC activation via the miR-495-3p/S1PR3 axis.</description><subject>Becaplermin - pharmacology</subject><subject>Biological Phenomena</subject><subject>Cell Proliferation</subject><subject>DNA Damage</subject><subject>hepatic fibrosis</subject><subject>hepatic stellate cells</subject><subject>Hepatic Stellate Cells - metabolism</subject><subject>Hepatic Stellate Cells - pathology</subject><subject>Humans</subject><subject>Liver Cirrhosis - genetics</subject><subject>Liver Cirrhosis - pathology</subject><subject>lncRNA NORAD</subject><subject>MicroRNAs - metabolism</subject><subject>miR-495-3p</subject><subject>Research Paper</subject><subject>RNA, Long Noncoding - metabolism</subject><subject>S1PR3</subject><subject>Sphingosine-1-Phosphate Receptors</subject><issn>2165-5979</issn><issn>2165-5987</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><recordid>eNp9UcmO1DAQjRCIGQ3zCSAfuWTGjuPtghgNq9QCCcHZqjhOt1FiB9vd0B_FP-LQi5gLF5er_BarXlU9J_iGYIlvG8IZU0LdNLhpykGFbMmj6nKZ10xJ8fh8F-qiuk7pO8aYYNoyIZ9WF5Q1f9vL6vcq-DXywdcm9K5cv3y6qx-2CEx2O8i2R90evSmDHiZYW-T8xnUuu-BR2s5ztCnZhDZ2huwMStmOY2EhU-pJY8HuHKDJmRgWq1axms63ad4Ut5Cct4jU8yaUwcKN1tg5h4gogl8uPaueDDAme32sV9W3d2-_3n-oV5_ff7y_W9Wm5TLXILmlrTCC0L7tuOzaATgz7UA7rjhVktFBKC6AdVb1XAgguGsIYIZ5C1LRq-rVQXfedpPtjfU5wqjn6CaIex3A6Ycv3m30Ouy0VKLIkyLw8igQw4-tTVlPLi2LAG_DNumG00YoSTEuUHaAlo2kFO1wtiFYL2nrU9p6SVsf0y68F__-8cw6ZVsArw8A54cQJ_gZ4tjrDPsxxCGCNy5p-n-PP7rSu0Y</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Zou, Lei</creator><creator>Shi, Cuifen</creator><creator>Wang, Dawei</creator><creator>Cheng, Juan</creator><creator>Wang, Qi</creator><creator>Wang, Lei</creator><creator>Yang, Guoya</creator><general>Taylor &amp; Francis</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220301</creationdate><title>Long non-coding RNA-non-coding RNA activated by DNA damage inhibition suppresses hepatic stellate cell activation via microRNA-495-3p/sphingosine 1-phosphate receptor 3 axis</title><author>Zou, Lei ; Shi, Cuifen ; Wang, Dawei ; Cheng, Juan ; Wang, Qi ; Wang, Lei ; Yang, Guoya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-a86e347c713d4b68b4fa65c4f3b69639853f7967a5be9d677a10b21a05064a893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Becaplermin - pharmacology</topic><topic>Biological Phenomena</topic><topic>Cell Proliferation</topic><topic>DNA Damage</topic><topic>hepatic fibrosis</topic><topic>hepatic stellate cells</topic><topic>Hepatic Stellate Cells - metabolism</topic><topic>Hepatic Stellate Cells - pathology</topic><topic>Humans</topic><topic>Liver Cirrhosis - genetics</topic><topic>Liver Cirrhosis - pathology</topic><topic>lncRNA NORAD</topic><topic>MicroRNAs - metabolism</topic><topic>miR-495-3p</topic><topic>Research Paper</topic><topic>RNA, Long Noncoding - metabolism</topic><topic>S1PR3</topic><topic>Sphingosine-1-Phosphate Receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zou, Lei</creatorcontrib><creatorcontrib>Shi, Cuifen</creatorcontrib><creatorcontrib>Wang, Dawei</creatorcontrib><creatorcontrib>Cheng, Juan</creatorcontrib><creatorcontrib>Wang, Qi</creatorcontrib><creatorcontrib>Wang, Lei</creatorcontrib><creatorcontrib>Yang, Guoya</creatorcontrib><collection>Taylor &amp; Francis Open Access(OpenAccess)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Bioengineered</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zou, Lei</au><au>Shi, Cuifen</au><au>Wang, Dawei</au><au>Cheng, Juan</au><au>Wang, Qi</au><au>Wang, Lei</au><au>Yang, Guoya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long non-coding RNA-non-coding RNA activated by DNA damage inhibition suppresses hepatic stellate cell activation via microRNA-495-3p/sphingosine 1-phosphate receptor 3 axis</atitle><jtitle>Bioengineered</jtitle><addtitle>Bioengineered</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>13</volume><issue>3</issue><spage>6150</spage><epage>6162</epage><pages>6150-6162</pages><issn>2165-5979</issn><eissn>2165-5987</eissn><abstract>Hepatic fibrosis is a damage repair response caused by multiple factors. A growing body of research suggests that long non-coding RNAs (lncRNAs) are involved in a wide range of biological processes, and thus regulate disease progression, including hepatic fibrosis. In this study, we investigated the mechanisms of the long non-coding RNA-non-coding RNA activated by DNA damage (NORAD) in modulating hepatic fibrosis development. Platelet-derived growth factor-BB (PDGF-BB) was used to activate LX-2 hepatic stellate cells (HSCs). The expression of NORAD and microRNA (miR)-495-3p was determined by quantitative real-time polymerase chain reaction (qRT-PCR) analysis. The effects of PDGF-BB on LX-2 cell viability, migration, invasion, and apoptosis were evaluated using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), Transwell, flow cytometry, and Western blot assays. The activation of HSCs was further verified by examining the expression of the typical markers, alpha smooth muscle actin (α-SMA) and collagen I (Col1α1), using qRT-PCR and Western blot assays. StarBase and dual-luciferase reporter assays were used to assess the binding relationship between miR-495-3p and NORAD. The NORAD levels remarkably increased, whereas the miR-495-3p levels decreased, in PDGF-BB-treated LX-2 cells. miR-495-3p was a putative downstream target of NORAD. NORAD silencing played an anti-fibrotic role by targeting miR-495-3p; this was accomplished by hindering PDGF-BB-treated LX-2 cell viability, migration, and invasion, decreasing the levels of α-SMA and Col1α1, and promoting apoptosis. miR-495-3p protected against hepatic fibrosis by inhibiting sphingosine 1-phosphate receptor 3 (S1PR3) expression. In summary, NORAD silencing inhibited hepatic fibrosis by suppressing HSC activation via the miR-495-3p/S1PR3 axis.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>35200103</pmid><doi>10.1080/21655979.2022.2037841</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2165-5979
ispartof Bioengineered, 2022-03, Vol.13 (3), p.6150-6162
issn 2165-5979
2165-5987
language eng
recordid cdi_proquest_miscellaneous_2632798300
source MEDLINE; Taylor & Francis Open Access(OpenAccess); PubMed (Medline); EZB Electronic Journals Library
subjects Becaplermin - pharmacology
Biological Phenomena
Cell Proliferation
DNA Damage
hepatic fibrosis
hepatic stellate cells
Hepatic Stellate Cells - metabolism
Hepatic Stellate Cells - pathology
Humans
Liver Cirrhosis - genetics
Liver Cirrhosis - pathology
lncRNA NORAD
MicroRNAs - metabolism
miR-495-3p
Research Paper
RNA, Long Noncoding - metabolism
S1PR3
Sphingosine-1-Phosphate Receptors
title Long non-coding RNA-non-coding RNA activated by DNA damage inhibition suppresses hepatic stellate cell activation via microRNA-495-3p/sphingosine 1-phosphate receptor 3 axis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T18%3A40%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%20non-coding%20RNA-non-coding%20RNA%20activated%20by%20DNA%20damage%20inhibition%20suppresses%20hepatic%20stellate%20cell%20activation%20via%20microRNA-495-3p/sphingosine%201-phosphate%20receptor%203%20axis&rft.jtitle=Bioengineered&rft.au=Zou,%20Lei&rft.date=2022-03-01&rft.volume=13&rft.issue=3&rft.spage=6150&rft.epage=6162&rft.pages=6150-6162&rft.issn=2165-5979&rft.eissn=2165-5987&rft_id=info:doi/10.1080/21655979.2022.2037841&rft_dat=%3Cproquest_pubme%3E2632798300%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2632798300&rft_id=info:pmid/35200103&rfr_iscdi=true